Tyra Biosciences (TYRA) Expected to Announce Earnings on Thursday

Tyra Biosciences (NASDAQ:TYRA) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 2, 2026 at 3:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.03). On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tyra Biosciences Stock Down 0.6%

Shares of NASDAQ:TYRA opened at $36.31 on Wednesday. Tyra Biosciences has a 52-week low of $6.42 and a 52-week high of $39.15. The stock’s fifty day simple moving average is $32.41 and its 200-day simple moving average is $23.32. The company has a market capitalization of $1.96 billion, a P/E ratio of -18.06 and a beta of 1.06.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds have recently made changes to their positions in TYRA. Caitong International Asset Management Co. Ltd acquired a new position in shares of Tyra Biosciences during the 4th quarter valued at $51,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares in the last quarter. Russell Investments Group Ltd. raised its position in Tyra Biosciences by 27.7% in the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after purchasing an additional 2,766 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Tyra Biosciences in the fourth quarter valued at about $220,000. Finally, VARCOV Co. acquired a new position in shares of Tyra Biosciences during the fourth quarter worth about $255,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. William Blair began coverage on shares of Tyra Biosciences in a research note on Tuesday, February 10th. They set an “outperform” rating on the stock. Piper Sandler lifted their price target on shares of Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a report on Friday, March 20th. Cantor Fitzgerald started coverage on shares of Tyra Biosciences in a research report on Tuesday, February 24th. They issued an “overweight” rating for the company. Finally, Barclays began coverage on shares of Tyra Biosciences in a research note on Tuesday, January 27th. They set an “overweight” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Tyra Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $44.67.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.